

**MOLECULAR VENTURES LIMITED
FINANCIAL STATEMENTS
FOR THE PERIOD 15 OCTOBER 2019 TO 31 OCTOBER 2020**

Lsd Accountants Ltd
Chartered Accountants
27 Stockwood Business Park
Redditch
Worcestershire
B96 6SX

Molecular Ventures Limited
Financial Statements
For the Period 15 October 2019 to 31 October 2020

Contents

	Page
Balance Sheet	1–2
Notes to the Financial Statements	3–4

Molecular Ventures Limited
Balance Sheet
As at 31 October 2020

Registered number: 12262067

		31 October 2020	
	Notes	£	£
FIXED ASSETS			
Investments	3		67,681
			<u>67,681</u>
CURRENT ASSETS			
Debtors	4	1	
Cash at bank and in hand		<u>362</u>	
			363
Creditors: Amounts Falling Due Within One Year	5	<u>(62,000)</u>	
NET CURRENT ASSETS (LIABILITIES)			<u>(61,637)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>6,044</u>
PROVISIONS FOR LIABILITIES			
Deferred Taxation			<u>(1,481)</u>
NET ASSETS			<u>4,563</u>
CAPITAL AND RESERVES			
Called up share capital	6		1
Fair Value Reserve	7		7,795
Profit and Loss Account			<u>(3,233)</u>
SHAREHOLDERS' FUNDS			<u>4,563</u>

Molecular Ventures Limited
Balance Sheet (continued)
As at 31 October 2020

For the period ending 31 October 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities

- The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
- The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr David Connolly

Director

06/01/2021

The notes on pages 3 to 4 form part of these financial statements.

Molecular Ventures Limited
Notes to the Financial Statements
For the Period 15 October 2019 to 31 October 2020

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

2. Average Number of Employees

Average number of employees, including directors, during the year was: 1

3. Investments

	Listed £
Cost	
As at 15 October 2019	-
Additions	59,886
Revaluations	7,795
As at 31 October 2020	<u>67,681</u>
Provision	
As at 15 October 2019	-
As at 31 October 2020	<u>-</u>
Net Book Value	
As at 31 October 2020	<u>67,681</u>
As at 15 October 2019	<u>-</u>

The investment portfolio is included at **fair** value.

Molecular Ventures Limited
Notes to the Financial Statements (continued)
For the Period 15 October 2019 to 31 October 2020

4. Debtors

	31 October 2020
	£
Due within one year	
Director's loan account	1
	<u>1</u>
	<u><u>1</u></u>

5. Creditors: Amounts Falling Due Within One Year

	31 October 2020
	£
Amounts owed to related parties (Current liabilities - creditors < 1 year)-Molecular Sound Limited	62,000
	<u>62,000</u>
	<u><u>62,000</u></u>

6. Share Capital

	31 October 2020
Allotted, Called up and fully paid	1
	<u>1</u>

During the period, 1 ordinary share of £1 was issued at par for cash consideration

7. Reserves

	Fair Value Reserve
	£
Fair value reserve	7,795
As at 31 October 2020	<u>7,795</u>
	<u><u>7,795</u></u>

8. Related Party Transactions

Included within other creditors is a balance of £62,000 owed to Molecular Sound Limited, a company in which Mr David Connolly is also a director. This balance is unsecured and interest free.

9. General Information

Molecular Ventures Limited is a private company, limited by shares, incorporated in England & Wales, registered number 12262067 . The registered office is 27 Stockwood Business Park, Stockwood, Redditch, England, B96 6SX.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.